Luspatercept-aamt 25 mg [Reblozyl]
RxNorm 2262908

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2262908 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: luspatercept-aamt 25 mg [Reblozyl].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Luspatercept-aamt 25 mg [Reblozyl]
AUI:11801809
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Luspatercept-aamt 25 mg [Reblozyl]
(Atom ID: 11801809)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
luspatercept-aamt 25 MG [Reblozyl]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2262908
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11801809
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2262908
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Luspatercept-aamt Injection


Luspatercept-aamt injection is used to treat anemia (a lower than normal number of red blood cells) in adults who are receiving blood transfusions to treat thalassemia (an inherited condition that causes a low number of red blood cells). Luspatercept-aamt injection is also used to treat anemia in adults with certain types of myelodysplastic syndrome (a group of conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells) and who are receiving blood transfusions, but have not responded to or cannot receive treatment with an erythropoiesis-stimulating agent (ESA). Luspatercept-aamt is in a class of medications called erythroid maturation agents. It works by increasing the number and quality of red blood cells.
[Learn More]


* Please review the disclaimer below.